Industry Briefs: Feb. 6, 2012
A roundup of other company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
FDA has approved Merck & Co.’s Janumet XR (sitagliptin and metformin HCl extended-release), a combination therapy for treating Type II diabetes.
Florida Biologix has announced that it now meets European GMP requirements for aseptic fill–finish.
NextPharma has opened a cold-chain and logistics warehouse in Werne, Germany.
OctoPlus and Ferring Pharmaceuticals have entered into a formulation development and manufacturing contract.
SCM Pharma has agreed to develop and manufacture an injectable neonatal product under development by BrePco BioPharma.
Sobi and Biogen Idec have updated their agreement regarding development and commercialization of long-lasting recombinant Factor VIII and Factor IX hemophilia programs, which includes Biogen Idec assuming manufacturing rights.
Xceleron is investing $2.4 million to locate all of the company’s business in its custom-built facility in Germantown, Maryland, which is expected to be fully operational by Mar. 31, 2012.
People News
Auxilium Pharmaceuticals has named Andrew I. Koven as executive vice-president, chief administrative officer, and general counsel, and has appointed Mark A. Glickman as senior vice-president of sales.
PCI Synthesis has made several executive appointments. Elie Saikali has been named director of manufacturing, and Mehdi Yazdi has been named director of quality control and analytical services. Don Dickinson has been named director of business development, and Paul Nichols has been appointed as director of cGMP for PCI’s early-phase clinical drug-substance development and manufacturing capabilities.
Syntagon has appointed quality assurance expert George Köllner to provide GMP and stand-alone duties.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.